Quality by Design Approaches to Formulation Robustness-An Antibody Case Study

Area of Science:

• Biopharmaceutical Science
• Formulation Development
• Quality by Design (QbD)

Background:

• International Conference on Harmonization Q8 (R2) mandates assessing formulation robustness.
• Formulation robustness is key to ensuring drug product quality and consistency.

Purpose of the Study:

• Propose a Quality by Design (QbD)-based definition for a robust biopharmaceutical formulation.
• Illustrate the definition with a case study involving a monoclonal antibody formulation.

Main Methods:

• Conducted a multivariate formulation robustness study for a monoclonal antibody.
• Evaluated product quality at target and edge-of-range compositions.
• Assessed end-of-shelf-life stability requirements (36 months at 2°C-8°C).

Main Results:

• Demonstrated acceptable quality across claimed formulation composition ranges.
• Extrapolated 24-month data to confirm end-of-shelf-life robustness.
• Monoclonal antibody formulation met stability requirements.

Conclusions:

• A formulation is robust if all critical quality attributes remain within acceptance criteria throughout the claimed composition range.
• The proposed definition and case study provide a framework for claiming formulation robustness.
• Robustness assessment is crucial for biopharmaceutical product development and lifecycle management.